Chenglin Jia

Chenglin Jia

Auto-generated profile, based on publicly available information

Chenglin Jia

Institute of Vascular Disease, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, 200082, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2023 in Phytomedicine
Verified
Journal Article
Closed access
ZZZhihui Zhang
Zhihui Zhang
YZYihan Zheng
Yihan Zheng
NCNan Chen
Nan Chen
CXChenqin Xu
Chenqin Xu
JDJie Deng
Jie Deng
YCYongbing Cao
Yongbing Cao

5 June 2014 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
QYQinbo Yang
Qinbo Yang
XWXiaoyan Wang
Xiaoyan Wang
JCJingang Cui
Jingang Cui
PWPeiwei Wang
Peiwei Wang
MXMinqi Xiong
Minqi Xiong
TZTeng Zhang
Teng Zhang
Panax Notoginseng Saponins (PNS) is the major class of active constituents of notoginseng, a natural product extensively used as a therapeutic agent in China. Tumor when accompanied by cardiovascular disorders poses a greater challenge for clinical management given the paradoxical involvement of angiogenesis, therefore gaining increased research attention. This study aim to investigate effects of PNS and its activity components in the mouse model of tumor complicated with myocardial ischemia.

19 January 2023 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
XQXiaojing Qian
Xiaojing Qian
SLShan Lin
Shan Lin
JLJi Li
Ji Li
CJChengLin Jia
ChengLin Jia
YLYun Luo
Yun Luo
YCYing Chen
Ying Chen
Diabetic nephropathy (DN) is one of the most severe microvascular complications of diabetes and has become the leading cause of end‐stage renal disease formation. The pathogenesis of diabetic nephropathy is very complex and is still not fully understood. Fisetin is a flavonoid polyphenolic compound that is widely found in different fruits, vegetables, and medicinal plants. Many studies have indicated that it has a variety of pharmacological activities. In this study, we investigated the mechanism of action of fisetin in the protection of DN‐induced podocyte injury both in vivo and in vitro. Results showed that fisetin could reduce high glucose (HG)‐induced podocyte injury and streptozotocin (STZ)‐induced diabetic nephropathy in mice. According to the histopathological staining results, fisetin ameliorated DN‐induced glomerular injury in a dose‐dependent manner. Western blot and immunofluorescence results showed that fisetin effectively promoted the expression of podocyte functional integrity marker proteins and inhibited the expression of podocyte injury marker proteins. In addition, according to the Western blot and RT‐qPCR results, fisetin activates the nuclear translocation of Nrf2 to exert antioxidative stress ability and affects the expression of downstream antioxidant enzymes HO‐1, GPX4, and other ferroptosis‐related markers, thereby protecting against HG‐induced podocyte ferroptosis and oxidative stress injury in DN mice. In summary, this study demonstrated that fisetin could enhance the antioxidative stress capacity of DN mice by promoting the activation of the Nrf2/HO‐1/GPX4 signaling pathway in renal tissues, and attenuated HG‐induced podocytes injury and STZ‐induced DN in mice.

7 September 2022 in Microbial Pathogenesis
Verified
Journal Article
Closed access
NCNan Chen
Nan Chen
JDJie Deng
Jie Deng
ZZZhihui Zhang
Zhihui Zhang
XFXia Feng
Xia Feng
HWHongkang Wang
Hongkang Wang
YCYongbing Cao
Yongbing Cao

18 August 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
DZDi Zhu
Di Zhu
CJChenglin Jia
Chenglin Jia
TCTongkai Cai
Tongkai Cai
JLJiacheng Li
Jiacheng Li
XFxia feng
xia feng
YCYemin Cao
Yemin Cao
Ruan jian qing mai recipe (RJQM) is an empirical prescription for treating arteriosclerosis obliterans (ASO). However, the mechanism of RJQM recipe-mediated ASO attenuation has not yet been elucidated. Therefore, this study aimed to explore the mechanism by which the RJQM recipe relieves ASO in a mouse model of lower limb ischemia, which was established by ligating and breaking the femoral artery of the left lower limb. The surgical groups were divided into the ischemic group, beraprost sodium group, low-dose RJQM group, medium-dose RJQM group, and high-dose RJQM group. Normal mice were set as the control group. The blood flow of the lower limb was examined on days 7 and 14. At the end of animal procedures, blood samples were collected, and the rectus femoris of the left lower limb were harvested. Results revealed that mice in the ischemic group demonstrated low blood flow. Additionally, hematoxylin and eosin, and Masson staining results showed that inflammation of the rectus femoris was obvious in the ischemia group, and the level of fibrosis was increased. Blood flow was recovered in all treatment groups compared to the ischemic group, and the inflammatory infiltration and fibrosis of the rectus femoris were relieved after RJQM treatment. The serum levels of interleukin (IL)-17A and IL-21 were decreased, and the expression of JAK2/STAT3 proteins was inhibited in all RJQM treatment groups compared to the ischemia group. Furthermore, the improvement of IL-17A, IL-21, and rectus femoris fibrosis was more obvious with increasing treatment time. In conclusion, RJQM can effectively alleviate ASO and promote the recovery of lower limb blood flow by regulating the JAK2/STAT3 signaling pathway to reduce the inflammatory response.

30 May 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
YJYujie Jiang
Yujie Jiang
XFXia Feng
Xia Feng
YYYuan Yin
Yuan Yin
CMChao Ma
Chao Ma
JDJie Deng
Jie Deng
CJChenglin Jia
Chenglin Jia